Gilead Sciences has submitted a Marketing Authorisation Application (MAA) for aztreonam lysine 75 mg powder for nebuliser solution (aztreonam lysine) in the EU. Aztreonam lysine is an investigational therapy in development for people with cystic fibrosis (CF) who have pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. Aztreonam lysine 75 mg powder for nebuliser solution is administered using an eFlow® Nebuliser (PARI GmbH). “Chronic pseudomonal airway infection represents the s...